Gene network and canonical pathway analysis in prostate cancer: A microarray study

Experimental and Molecular Medicine

Volumn 40, Issue 2, 2008, Pages 176-185

  Savli, Hakan ^a   Szendröi, Attila ^b   Romics, Imre ^b   Nagy, Balint ^c  

^a KOCAELI UNIVERSITY   (Turkey)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Microarray analysis; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

COMPLEMENTARY DNA; CYTOSKELETON PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C;

ACUTE PHASE RESPONSE; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; DIGITAL RECTAL EXAMINATION; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE SYNTHESIS; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MALE; MICROARRAY ANALYSIS; NEEDLE BIOPSY; PATIENT SELECTION; PROSTATE CANCER; PROSTATE HYPERTROPHY; RNA ISOLATION; SIGNAL TRANSDUCTION;

EID: 44349119764     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2008.40.2.176     Document Type: Article

References (48)

1. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410-34
2. Akashi T, Koizumi K, Nagakawa O, Fuse H, Saiki I. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in PCA DU-145. Oncol Rep 2006;16:831-6
3. Akdogan M, Hassoun BS, Gurakar A, El-Sahwi K, Jazzar A, Wright H, Sebastian A, Nour B. Prostate-specific antigen levels among cirrhotic patients. Int J Biol Markers 2002;17:161-4
4. Albrecht M, Doroszewicz J, Gillen S, Gomes I, Wilhelm B, Stief T, Aumüller G. Proliferation of PCA cells and activity of neutral endopeptidase is regulated by bombesin and IL-1beta with IL-1beta acting as a modulator of cellular differentiation. Prostate 2004;58:82-94
5. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 2007;67:4244-53
6. Benbrahim-Tallaa L, Waterland RA, Styblo M, Achanzar WE, Webber MM, Waalkes MP. Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrantgenomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol 2005;206:288-98
7. Benbrahim-Tallaa L, Webber MM, Waalkes MP. Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. Environ Health Perspect 2007;115:243-7
8. Bern MM. Coagulopathy, following medical therapy, for carcinoma of the prostate. Hematology 2005;10:65-8
9. Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res 2003;63:6387-94
10. Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003;9:1087-97
11. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007;75:831-42
12. Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC, Chen JH. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 2007;14:84-93
13. Cho SY, Lee EY, Lee JS, Kim HY, Park JM, Kwon MS, Park YK, Lee HJ, Kang MJ, Kim JY, Yoo JS, Park SJ, Cho JW, Kim HS, Paik YK. Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics 2005;5:3386-96
14. Dai S, Wang X, Liu L, Liu J, Wu S, Huang L, Xiao X, He D. Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum. Sci China C Life Sci 2007;50:305-11
15. Dimitroff CJ, Lechpammer M, Long-Woodward D, Kutok JL. Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin. Cancer Res 2004;64:5261-9
16. Duran I, Tannock IF. Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. J Gen Intern Med 2007;22:1062
17. Engl T, Relja B, Blumenberg C, Müller I, Ringel EM, Beecken WD, Jonas D, Blaheta RA. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006;78:1784-93
18. Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE, Beijnen JH. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest 2007;87:161-72
19. George NJ. Prostate cancer biology, diagnosis and management. Surg Oncol 2003;12: 211
20. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, Leung HY. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005;92:320-7
21. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20
22. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of PCA. J Clin Path 2005;58:673-84
23. Iacopino F, Angelucci C, Lama G, Zelano G, La Torre G, D'Addessi A, Giovannini C, Bertaccini A, Macaluso MP, Martorana G, Sica G. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma. Anticancer Res 2006;26:1849-54
24. Ishigami T, Uzawa K, Higo M, Nomura H, Saito K, Kato Y, Nakashima D, Shiiba M, Bukawa H, Yokoe H, Kawata T, Ito H, Tanzawa H. Genes and molecular pathways related to radioresistance of oral squamous cell carcinoma cells. Int J Cancer 2007;120:2262-70
25. Konishi N. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 1992;69:2293-9
26. Kovacevic A, Hammer A, Sundl M, Pfister B, Hrzenjak A, Ray A, Ray BK, Sattler W, Malle E. Expression of serum amyloid A transcripts in human trophoblast and fetal-derived trophoblast-like choriocarcinoma cells. FEBS Lett 2006;580:161-7
27. Kovacevic A, Hammer A, Stadelmeyer E, Windischhofer W, Sundl M, Ray A, Schweighofer N, Friedl G, Windhager R, Sattler W, Malle E. Expression of serum amyloid A transcripts in human bone tissues, differentiated osteoblast-like stem cells and human osteosarcoma cell lines. J Cell Biochem 2008;103:994-1004
28. Kubota Y, Sasagawa I, Sinzawa H, Kunii T, Itoh K, Miura H, Imai K, Nakada T. Serum levels of free and total prostate-specific antigen in males with liver cirrhosis. Eur Urol 1999;36:409-12
29. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 2001;46:163-72
30. Liu F, Jenssen TK, Trimarchi J, Punzo C, Cepko CL, Ohno-Machado L, Hoviq E, Patrick Kuo W. Comparison of hybridization-based and sequencing-based gene expression technologies on biological replicates. BMC Genomics 2007;8:153
31. Liu HL, Gandour-Edwards R, Lara PN Jr, de Vere White R, LaSalle JM. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. J Cancer 2001;7:395-403
32. Maitland NJ, Collins A. A tumour stem cell hypothesis for the origins of PCA. BJU Int 2005;96:1219-23
33. Marelli MM, Moretti RM, Procacci P, Motta M, Limonta P. Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. Int J Oncol 2006;28:723-30
34. McDonnell TJ. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4
35. Moore TM, Garg R, Johnson C, Coptcoat MJ, Ridley AJ, Morris JD. PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization. J Biol Chem 2000;275:4311-22
36. Müller H, Brenner H. Urine markers as possible tools for PCA screening: review of performance characteristics and practicality. Clin Chem 2006;52:562-73
37. Navarro M, Ruiz I, Martin G, Cruz JJ. Patient with disseminated intravascular coagulation as the first manifestation of adenocarcinoma of the prostate. Risks of prostatic biopsy. Prostate Cancer Prostatic Dis 2006;9:190-1
38. Nelson MA, Porterfield BW, Jacobs ET, Clark LC. Selenium and prostate cancer prevention. Semin Urol Oncol 1999;17:91-6
39. Papakonstanti EA, Kampa M, Castanas E, Stournaras C. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol 2003;17:870-81
40. Quinn DI, Henshall SM, Sutherland LR. Molecular markers of PCA outcome. Eur J Cancer 2005;41:858-87
41. Savli H, Aalto Y, Nagy B, Knuutila S, Pakkala S. Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: a cDNA array study. Br J Haematol 2002;118:1065-70
42. Shirai K, Chaudhary UB. Use of low molecular weight heparin and aminocaproic acid in chronic DIC associated with prostate cancer - a case report. Scientific World J 2007;7:753-5
43. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, Konaka H, Namiki M, Tozawa K, Kohri K, Tanji N, Yokoyama M, Shimazui T, Akaza H, Mizutani Y, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007;67:5117-25
44. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana- Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chiannaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51
45. Uemura H, Ishiguro H, Kubota Y. Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Rev Med Chem 2006;6:835-44
46. Ullén A, Lennartsson L, Harmenberg U, Lennernäs B, Majumder K, Holmberg AR, Nilsson S, Elmberger GP. Prostate cancer cell lines lack amplification: overexpression of HER2. Acta Oncol 2005;44:490-5
47. Wells CM, Ahmed T, Masters JR, Jones GE. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil Cytoskeleton 2005;62:180-94
48. Wu Z, McRoberts KS, Theodorescu D. The role of PTEN in prostate cancer cell tropism to the bone micro-environment. Carcinogenesis 2007;28:1393-400